ISRG Intuitive Surgical, Inc.

Intuitive Surgical has delivered a 43.1% gain over the past three years, even as the stock has been weaker more recently. This puts fresh focus on whether the current US$412.18 share price is properly backed by the cash the business can generate. With new headlines around robotic surgery and strong recent revenue figures, the key issue now is how that share price lines up against the value implied by its cash flows. The 43.1% return over three years means anyone looking at Intuitive Surgical...

Visa, Intuitive Surgical and Williams Companies headline today's research, with growth opportunities balanced by margin, valuation and execution risks.

Look at the breakdown of Intuitive Surgical's revenue streams—Instruments and Accessories alone generate roughly 60% of the top line on a per-procedure basis. That tight link between surgery volume and cash flow explains why investors reacted so sharply when Intuitive noted in its fiscal Q2 2026 call that U.S. procedure growth had slowed. With recurring earnings visibility clouded, how much downside risk is the market actually pricing in.

Zacks.com users have recently been watching Intuitive Surgical (ISRG) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

At first glance, Gilead Sciences, Inc. (NASDAQ:GILD) and Intuitive Surgical, Inc. (NASDAQ:ISRG) don’t make for the most obvious comparison. One sells medicines led by a massive HIV franchise, while the other has built its business around robotic surgery. Yet both have given investors a similar reason to pay attention this year, which is that growth […]

Intuitive Surgical (ISRG) shares fell 10.4% in the past year, while the S&P 500 returned 16.5%. Much of the market has focused on moderating U.S. procedure growth. The more telling number is 144 trade-ins in fiscal Q2 2026, up from 83 a year earlier. Most came from customers moving to the new da Vinci 5 robot. Those trade-ins matter most if upgrades continue and each surgery also earns more. Is that number a blip, or are customers still trading up.

AI adoption is reshaping medical devices, with ISRG, TEM and TMO leveraging AI to advance precision medicine and drug development.

Wall Street thinks that this robotic surgical systems leader's sell-off is overdone.

ISRG's rapid procedure growth, expanding robotics ecosystem and recurring revenues highlight its growth path amid MedTech shifts.

The market may be underestimating these companies.

Earlier this month, Intuitive Surgical received CE mark approval for using its da Vinci SP single-port robotic system in transvaginal gynecologic procedures, adding to its existing approvals for a range of endoscopic and natural-orifice surgeries across Europe. This world's-first indication for the SP platform deepens Intuitive’s position in minimally invasive, scarless surgery by broadening its clinically supported use in complex anatomical spaces. We’ll now examine how this expanded...

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

Abbott leads in absolute revenue, but Intuitive Surgical's growth rate tells a different story over the past eight quarters.

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the surgical equipment & consumables - specialty stocks, including Intuitive Surgical (NASDAQ:ISRG) and its peers.

Intuitive Surgical is expanding robotic surgery in ASCs with lower-cost XiR systems, opening access to new customers and outpatient procedures.

Intuitive Surgical (ISRG) stock could climb 23.9% to the April high it last fell back from, and you would risk about 5% to find out. That looks like a surgical-robot leader on sale, but the price history disagrees. Over the last two years, none of its visits to this price range turned into a 20% gain before a 5% drop.

Intuitive Surgical (ISRG) has lost about 12% over the past year, while the S&P 500 returned about 17%. Most of the debate has been about the U.S. procedure growth slowing. The number that should worry a holder more is the money the company collects on the instruments used in each operation. Intuitive plans to lower it.

The company is in the process of expanding the uses for its Hugo Surgical System and expanding its revenue base.

Intuitive Surgical (ISRG), maker of the da Vinci surgical robots, trades at about $382, some 36% below its 52-week high. Even so, you pay about 35.9 times trailing adjusted earnings. That is normalized net income with stock-based compensation added back, a basis meant to sit closer to the one analysts forecast on, though the two are not defined identically. Analysts' forecasts run to 2027, the year Intuitive plans to start lowering what customers pay per use on some instruments.

Companies with more cash than debt often have stronger financial flexibility, making them attractive in uncertain markets. With interest payments less of a worry, these businesses can invest more in growth, innovation, or buybacks and dividends.

Intuitive Surgical's CE mark expands da Vinci SP into transvaginal gynecology in Europe, opening a new women's health opportunity and growth runway.

Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.

Intuitive Surgical (NasdaqGS:ISRG) received the world's first CE mark for transvaginal gynecologic procedures using its da Vinci SP system. The approval expands the da Vinci SP platform's labeled use in Europe to include transvaginal access for gynecologic surgery. The CE mark positions Intuitive Surgical as an early mover in single port, natural orifice gynecologic procedures in the region. The new CE mark for transvaginal gynecologic use is only one part of the broader Intuitive Surgical...

Intuitive Surgical's da Vinci meta-analysis across 14 million procedures found better perioperative outcomes versus laparoscopic and open surgery.

In the closing of the recent trading day, Intuitive Surgical, Inc. (ISRG) stood at $377.94, denoting a +2.38% move from the preceding trading day.

ISRG is using AI, software, data and advanced instruments to strengthen da Vinci 5 and stay ahead as robotic surgery competition intensifies.

Intuitive Surgical (ISRG) trades near $370, about 38% below its 52-week high, after growth in its US robotic-surgery procedures slowed. Selling a put pays you now for agreeing to buy the shares much lower, and you keep the payment either way. The catch is it only works if you would want this business at that price.

A major bank just dropped a forecast that reframes the entire robotics industry, and the ripple effects are already moving stock prices across chips, foundries, and factory floors. Here is what the number means for long-term investors.

Intuitive Surgical (NASDAQ:ISRG) executives said the company remains focused on global procedure growth, while acknowledging a recent deceleration in U.S. procedures and policy-related uncertainty affecting hospitals. Speaking at a Wells Fargo conference, Executive Vice President, CFO and Enterpris

Stock Market Today: The Dow Jones index rallies Friday after a surprise CPI inflation report. Nvidia stock rebounded in morning trading.

The Global X Robotics & Artificial Intelligence ETF (BOTZ) has fallen more than 8% over five years due to heavy industrial automation exposure, concentration risk, and weak holdings like Tesla and Baidu.

Intuitive Surgical (ISRG) has handed its owners a hard year. The stock is down 25% over the trailing twelve months while the S&P 500 returned 19.3%, and it now trades about 41% below its 52-week high. After a fall like that the natural hope is that the big moves are behind you. Options priced a year out say they are not.

Based on the average brokerage recommendation (ABR), Intuitive Surgical (ISRG) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Intuitive Surgical trades at its cheapest valuation in 10 years as strong growth, innovation and procedure gains face rising costs and market pressures.

Medtronic has a historically high 3% yield and is just two years away from becoming a Dividend King.

Intuitive Surgical, Inc. (ISRG) closed the most recent trading day at $350.16, moving 4.51% from the previous trading session.

BOTZ offers diversified exposure to a robotics boom fueled by AI, humanoid robots and industrial automation, as the sector rapidly evolves.

Intuitive Surgical's Ion platform is gaining momentum, with rising procedures, a larger installed base and global expansion fueling a second growth engine.

Sands Capital, an investment management company, released its second-quarter 2026 investor letter for “Sands Capital Global Growth Fund”. The letter can be downloaded here. Global Growth seeks the best growth businesses worldwide, leveraging a research team that explores both developed and emerging markets for sustainable competitive advantages. In the quarter, global equities rebounded strongly, driven […]

Intuitive Surgical's flywheel isn't selling new surgical robots, its selling parts and services to support the ones it has already sold.

You might regret ignoring these companies at current levels.

Both Intuitive Surgical and Stryker just posted their fifth straight earnings beat, and Wall Street is cheering for both. But a structural difference buried inside their business models quietly separates a compounder from a cyclical recovery story.

In the world of robotic surgery, one company is both the undisputed leader and the most expensive option, forcing investors to ask if operational excellence is worth the premium.

The stock has dropped more than 30% this year.

Intuitive Surgical has notably underperformed the Health Care Equipment industry over the past year, but analysts are highly optimistic about the stock’s prospects.

Intuitive Surgical is boosting R&D despite macro headwinds, targeting AI, robotics and new procedures to expand its market and drive long-term growth.

Medtronic stock advances after the company posts better-than-expected quarterly earnings, raises revenue guidance, and announces a $700 million investment.

In the most recent trading session, Intuitive Surgical, Inc. (ISRG) closed at $372.6, indicating a +1.51% shift from the previous trading day.

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

This is a market-broadening year for Intuitive Surgical. The company is expanding beyond its core da Vinci systems to serve a wider continuum of hospitals and surgery centers.